Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000124523 | SCV000167956 | benign | not specified | 2012-11-29 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Labcorp Genetics |
RCV001082631 | SCV000261432 | benign | Ehlers-Danlos syndrome, classic type, 1 | 2025-02-04 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000587095 | SCV000696671 | benign | not provided | 2017-03-21 | criteria provided, single submitter | clinical testing | Variant summary: The COL5A2 c.315A>C (p.Thr105Thr) variant involves the alteration of a non-conserved nucleotide, resulting in a synonymous change. One in silico tool predicts a benign outcome for this variant. 5/5 splice prediction tools predict no significant impact on normal splicing and ESE finder predicts that this variant does not significantly impact ESE sites at the locus. However, these predictions have yet to be confirmed by functional studies. This variant was found in the large control database ExAC at a frequency of 0.9322042 (113164/121394 control chromosomes [53063 homozygotes]), making it the major allele at this genomic location. At the frequency, the variant is approximately 745763 times the estimated maximal expected allele frequency of a pathogenic COL5A2 variant (0.0000013), suggesting it is likely a benign polymorphism. In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as benign. To our knowledge, the variant of interest has not been reported in affected individuals via publications, nor has it been evaluated for functional impact by in vivo/vitro studies. Taken together, this variant is classified as benign. |